Africa is the world’s fastest-growing pharmaceutical market — and it is still only beginning to unlock its potential.

A continent of 1.4 billion people, a median age of 19, a rapidly urbanising population, and governments under sustained pressure to improve public health outcomes: the structural conditions for pharmaceutical market growth in sub-Saharan Africa are stronger today than at any previous point in history. The question is no longer whether the market will grow — it is who will be positioned to capture that growth.

Key Market Metrics

Market size (2024)

$46B

Sub-Saharan Africa pharma

Projected size (2030)

$78B

Est. at current CAGR

CAGR 2024–2030

9.2%

vs ~4% global average

Import dependency

>70%

Import dependency

Market Size Projection (2020–2030)

The sub-Saharan African pharmaceutical market has grown from an estimated $28 billion in 2020 to $46 billion in 2024, representing a compound annual growth rate of approximately 9.2% — more than double the global pharmaceutical market average. Projections based on current demographic, economic, and health system trends place the market at $78 billion by 2030, with several high-growth corridors — including West and Central Africa — likely to outperform that average.

Key Market Size Projection (2020-2030)

Year

Market size (USD B)

2020

$28B

2022

$35B

2024

$46B

2027 (proj.)

$62B

2030 (proj.)

$28B

Key Growth Drivers

Demographic pressure

Sub-Saharan Africa will add 800 million people by 2050. A young, rapidly urbanising population translates directly into rising demand for primary care, chronic disease management, and preventive medicine — all underpinned by pharmaceutical consumption. With a median age of just 19 years and a fertility rate that sustains population growth well into the second half of the century, the market’s demand base is structurally expanding in ways that no other region in the world can match.

Healthcare infrastructure investment

Governments across West and Central Africa are significantly increasing public health budgets. The African Union’s Agenda 2063 and national health plans have triggered unprecedented infrastructure spending — new hospitals, pharmacy networks, cold-chain logistics, and digital health registries — expanding the addressable market for quality medicines. Countries like Senegal and Gabon have launched ambitious universal health coverage programmes that are creating structured, recurring procurement demand.

International health financing

Programmes from the Global Fund, GAVI, UNICEF, and bilateral donors continue to channel billions into African health systems annually. These programmes create structured procurement channels — often with preference for WHO-prequalified or stringently regulated products — that directly benefit quality-certified international laboratories seeking market entry without bearing the full cost of demand creation.

Rising middle class and out-of-pocket spending

A growing middle class — projected to reach 1.1 billion by 2060 — is shifting from public to private healthcare, increasing out-of-pocket expenditure on branded, quality medicines and creating a premium market segment that barely existed a decade ago. Retail pharmacy chains are expanding rapidly in capitals and secondary cities, creating new channels for branded pharmaceutical products that operate outside the traditional public tender system.

Why Now Is the Right Time to Enter

The African pharmaceutical market is at an inflection point. Regulatory frameworks are maturing. Procurement systems are becoming more structured and transparent. International donor programmes are creating durable demand for quality-certified products. And the competitive landscape, while growing, has not yet reached the saturation levels that characterise more established emerging markets.

For laboratories that enter now — with the right local partners, the right regulatory strategy, and the right commercial infrastructure — the window to establish durable market positions and long-term distribution relationships is open. It will not remain open indefinitely.

MednAfrica exists precisely to help quality-focused international laboratories move through that window with confidence, speed, and the local intelligence that makes the difference between a launch and a foothold.